<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="26537">Retinoids</z:chebi> are important regulators of cell growth and differentiation in vitro and in vivo and they exert their biologic activities by binding to nuclear <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptors (RARs; alpha, beta, and gamma) and <z:chebi fb="0" ids="26537">retinoid</z:chebi> X receptors (RXRs; alpha, beta, and gamma) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (RA) induces complete remission in patients with <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL) presumably by binding directly to RAR alpha of APL cells </plain></SENT>
<SENT sid="2" pm="."><plain>Leukemic blasts from APL patients initially responsive to RA can become resistant to the agent </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 myeloblasts cultured with RA have developed mutations of the ligand-binding region of RAR alpha and have become resistant to RA </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, insertion of an RAR alpha with an alteration in the ligand-binding region into <z:mpath ids='MPATH_458'>normal</z:mpath> murine bone marrow cells can result in growth factor-dependent immortalization of the early hematopoietic cells </plain></SENT>
<SENT sid="5" pm="."><plain>To determine if alterations of the ligand binding domain of RAR alpha might be involved in several malignant <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e>, the mutational status of this region (exons 7, 8, and 9) was examined in 118 samples that included a variety of cell lines and fresh cells from patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), including 20 APL patients, 5 of whom were resistant to RA and 1 who was refractory to RA at diagnosis, using polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) analysis and DNA sequencing </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, 7 of the 20 APLs were studied for alterations of the other coding exons of the gene (exons 2 through 6) </plain></SENT>
<SENT sid="7" pm="."><plain>No mutations of RAR alpha were detected </plain></SENT>
<SENT sid="8" pm="."><plain>Although the sensitivity of PCR-SSCP analysis is less than 100%, these findings suggest that alterations of RAR alpha gene are rare and therefore other mechanisms must be involved in the <z:hpo ids='HP_0003674'>onset</z:hpo> of resistance to <z:chebi fb="0" ids="26537">retinoids</z:chebi> and in the lack of differentiation in disorders of the myeloid lineage </plain></SENT>
</text></document>